S
SELLAS LIFE SCIENCES GROUP INC
NASDAQ: SLS (SELLAS Life Sciences Group, Inc)
Last update: 1 hour ago13.21
-2.00 (-13.15%)
| Previous Close | 15.21 |
| Volume | 9,757,807 |
| Price / Sales | 26.90 |
| Price / Book | 22.32 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.360 |
| Total Debt/Equity (MRQ) | 3.13% |
| Current Ratio (MRQ) | 4.64 |
| Operating Cash Flow (TTM) | -33.71 M |
| Levered Free Cash Flow (TTM) | -23.98 M |
| Return on Assets (TTM) | -58.79% |
| Return on Equity (TTM) | -144.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | SELLAS Life Sciences Group, Inc | Mixed | Bullish |
AIStockmoo Score
1.2
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.17 |
|
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.34% |
| % Held by Institutions | 14.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dagco, Inc. | 30 Jun 2026 | 1,232,433 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |